Brooklyn ImmunoTherapeutics Accounts Payable

Brooklyn ImmunoTherapeutics (BTX) currently reports a accounts payable of $5.3M as of June 2026. That compares with $14M in the prior-year period — down 62.6% year over year. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's accounts payable history and peer comparisons.

Brooklyn ImmunoTherapeutics's accounts payable decreased from $14M to $5.3M — a 62.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brooklyn ImmunoTherapeutics reported $5.3M in accounts payable as of June 2026. That compares with $14M in the prior-year period — down 62.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $5.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On accounts payable, it currently shows $5.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.